Life After Big Pharma

It’s hard to get precise figures of how many people have been taken off the payroll at pharma and biotech companies recently. According to staffing firm, Challender, Gray and Christmas, the combined industries shed 58,969 jobs in the first nine months of 2009, 15,000 more than the whole of 2008. In total, that makes around 74,000 redundancies in just 21 months, many but not all of which came from sales forces. Figures from FiercePharma, meanwhile, show just ten companies saw 66,850 jobs go in 2009. And this doesn’t include layoffs from the merger of Roche and Genentech, nor the 860 jobs that were announced at Boehringer Ingelheim in August. Read more »

PhRMA Details Its Proposal for Internet and Social-Media Standards

Patricia Van Arnum PharmTech editor Company websites, news websites, other content-based websites, and microblogging sites such as Twitter, are important vehicles of communication for disseminating information. A challenge for stakeholders in the pharmaceutical industry—the public at large, patients, medical personnel, drug companies, and regulators—is to have a mechanism for how that information can be effectively and responsibly communicated. Read more »

The Unregulated Regulator

Erik Greb PharmTech editorWe all depend on the US Food and Drug Administration to enforce standards that keep our drugs safe. We expect the agency to set clear guidelines for consumers and manufacturers to follow. We also assume that the agency has standards for its own activities and ways of ensuring that agents comply with those standards. Unfortunately, a recent report from the US Government Accountability Office (GAO) shows that FDA has not entirely lived up to our expectations. Read more »

Rx-360 Goals Get off the Ground

Angie Drakulich PharmTech editorMany companies throughout industry are depending on Rx-360, the international pharmaceutical supply-chain consortium launched last year, to help ease the burden of protecting their ever-lengthening supply chains. Read more »

US and Europe At Risk from Substandard Medicines

When most of us look at taking a new medicine we tend to think it will make us better. Some of us may think about possible side effects but few of us expect the medicines we take to actually be dangerous. Recently, the public and policymakers have become more aware of the issue of counterfeit medicines — especially as patients increasingly learn about how to shop safely online for pharmaceuticals. But scant attention has been paid to a safety issue that is also important to patients — the problem of substandard medicines. Read more »

What is Next in Patent Reform?

Patricia Van Arnum PharmTech editor Although the healthcare debate has dominated the news headlines as of late, an equally important consideration for the pharmaceutical industry is the effort by Congress to pass legislation on patent reform. Congress may be moving closing to that goal. On Feb. 25, Sen. Patrick Leahy (D-VT), chairman of the Senate Judiciary Committee, issued a statement that lawmakers have reached a tentative agreement on reforming the country’s patent system. Read more »

Who Will Lead PhRMA?

Patricia Van Arnum PharmTech editor The Pharmaceutical Research and Manufacturers of America’s (PhRMA) announcement earlier this month that current President and CEO Billy Tauzin will step down at the end of June has raised the question of who will lead the association representing the innovator-drug industry. PhRMA says that it has already begun a search, so what are some of the key issues that the association should consider in finding a new chief policy advocate? Read more »

Ombudsman and Superman

Attention has frequently been drawn to the complexities of getting anything done in Europe. A brilliant researcher can explore visionary horizons, an ambitious entrepreneur can offer a package of goods or services of inestimable value, but the degree of control and regulation becomes more intense every year — sometimes every month or week. Read more »

Obama reform plan features curbs on drug spending

Jill Wechsler Washington EditorThe health reform proposal unveiled by the White House on Feb. 22, 2010 retains a number of provisions that directly affect drug coverage and industry revenues. The plan highlights that it will close the Medicare drug benefit “doughnut hole” by 2020 to make drugs more affordable to the elderly. Seniors will get some relief this year through a $250 rebate, and coinsurance will phase down over the next decade. Read more »

The Unkindest Cuts of All

Erik Greb PharmTech editorThese days, mandatory furloughs and staff cuts have employees in all industries nervously glancing over their shoulders. The pharmaceutical industry is no exception. Last week, Merck (Whitehouse Station, NJ) revealed plans to reduce its workforce by 15% by the end of 2012. Read more »

Next Page »